BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38501390)

  • 1. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Karri V; Lin H; Velazquez J; Batajoo A; Parekh D; Stanton W; Abhyankar H; El-Mallawany NK; Agrusa J; Eckstein O; Gulati N; Schwartz J; Woods-Swafford W; Boyd J; Saha A; Allen CE; McClain KL
    Br J Haematol; 2024 May; 204(5):1882-1887. PubMed ID: 38501390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies.
    Diamond A
    Br J Haematol; 2024 May; 204(5):1588-1589. PubMed ID: 38606542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Parekh D; Lin H; Batajoo A; Peckham-Gregory E; Karri V; Stanton W; Scull B; Fleishmann R; El-Mallawany N; Eckstein OS; Prudowsky ZD; Gulati N; Agrusa JE; Ahmed AZ; Chu R; Dietz MS; Goldman SC; Hogarty MD; Imran H; Intzes S; Kim JM; Kopp LM; Levy CF; Neff P; Pillai PM; Sisk BA; Schiff DE; Trobaugh-Lotrario AD; Walkovich K; McClain KL; Allen CE
    Br J Haematol; 2024 May; 204(5):1888-1893. PubMed ID: 38501389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
    McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
    Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Langerhans cell histiocytosis.
    Rodriguez-Galindo C; Allen CE
    Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
    Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
    Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.
    Abla O
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):386-395. PubMed ID: 38066856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
    J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.
    Bahabri A; Abla O
    Expert Rev Hematol; 2024 Jun; 17(6):223-231. PubMed ID: 38721670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
    Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
    Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
    Arceci RJ; Allen CE; Dunkel IJ; Jacobsen E; Whitlock J; Vassallo R; Morris SR; Portnoy A; Reedy BA; Smith DA; Noble R; Murnane A; Cornfeld M; Rodriguez-Galindo C; Heaney ML; McClain K; Vaiselbuh S
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27804235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success of Trametinib in the Treatment of Langerhans Cell Histiocytosis With Novel MAPK Pathway Mutations.
    Orr K; Hustak S; Beaudoin R; Ray A
    J Pediatr Hematol Oncol; 2023 May; 45(4):e534-e538. PubMed ID: 36730444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
    Li Q
    J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.
    Mohapatra D; Gupta AK; Haldar P; Meena JP; Tanwar P; Seth R
    Pediatr Hematol Oncol; 2023 Feb; 40(1):86-97. PubMed ID: 35616365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.